Antibody-based therapeutics are advancing in clinical development at a rapid rate and being approved in record numbers.
To keep our members up to date on recent events, we compile relevant information from news releases and other sources, and send this “Antibody News You Should Know” to our members via email twice per month. We include news about:
- Clinical studies started recently, focusing on the first Phase 1, Phase 2 or Phase 3 study
- Submission of marketing applications
- Marketing approvals
- Licensing deals
- Regulatory agency designations granted (e.g., Orphan Drug, PRIME, Breakthrough Therapy, Priority review)
As of March 15, 2020, we are featuring in-depth coverage of news related to COVID-19 biologic interventions.
As a service to the community, The Antibody Society offers access to past “Antibody News You Should Know”, which can be accessed via links below. “Antibody News” have also been compiled into PDFs for convenience. The PDFs, which can be downloaded via links below, include links to the original source and can be searched by keywords (e.g., SARS-CoV-2, bispecific, antibody-drug conjugate).
If you are not already a Society member, please register to receive bi-monthly Antibody News delivered by email.
2021 Antibody News You Should Know
Antibody News from 2021 will be added here.
2020 Antibody News You Should Know
Click here for PDF of Antibody News from H2 2020 (Jul-Dec).
Click here for PDF of Antibody News from Q2 2020 (Apr-Jun).
Click here for PDF of Antibody News from Q1 2020 (Jan-Mar).
2019 Antibody News You Should Know
Click here for PDF of Antibody News from Apr 15-Dec 31, 2019
